copiktra/duvelisib approv ahead pdufa
verastem copiktra duvelisib novel inhibitor receiv fda
approv relapsed/refractori cll/sll prior therapi
acceler approv relapsed/ refractori follicular lymphoma fl
prior therapi confirmatori trial fl requir approv come
copiktra receiv fda prioriti review expect label carri
materi warn fatal seriou
cutan reaction pneumon manag rem
copiktra avail week continu estim us peak
revenu intern initi indic
approv line cll/sll popul mpf copiktra
mo vs mo control compar mo respect
overal studi verastem set list price gener in-lin
estim continu model peak us penetr copiktra
cll/sll patient patient treat
line feel adequ reflect potenti label
copiktra uniqu pharmacolog inhibit delta
gamma isoform copiktra attack malign cell
directli disrupt tumor microenviron potenti
better safety/toler compar select inhibitor
copiktra cll/sll result line cll/sll signific
clinic meaning mo vs mo hr cll ibrutinib
move front line provid room copiktra refractori set
though firm complianc prophylact regimen necessari
manag believ demograph treatment trend favor
copiktra cll estim could reach cll
copiktra fl promis potenti though smaller indic
cll fl patient could earli adopt copiktra orr
shown label refractori set appear meaning
unmet need refractori fl set materi
vstm appear attract vstm stand-alon npv driven
copiktra potenti lift pt
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
verastem biopharmaceut compani headquart needham mass
focus develop cancer therapeut advanc
program copiktra duvelisib defactinib progress clinic studi
multipl indic exhibit copiktra verastem materi asset
first-in-class molecul target phosphoinositid
central signal pathway cancer prolifer surviv
copiktra novel dual inhibit delta gamma isoform
copiktra directli attack malign b-cell t-cell believ
materi disrupt tumor microenviron copiktra approv
septemb line cll/sll line fl
exhibit verastem pipelin copiktra duvelisib defactinib focus
copiktra highli activ relapsed/refractori cll/sll follicular
lymphoma yield fda prioriti review dual delta
gamma inhibit activ copiktra demonstr solid activ
number set produc encourag result sever trial includ
duo phase studi patient relaps refractori chronic
sll
dynamo phase monotherapi studi patient refractori indol non-
hodgkin lymphoma inhl copiktra abl demonstr rapid
statist signific clinic meaning activ cll/sll duo
mo vs mo compar hr exhibit
overal studi popul well robust respons
challeng delet subpopul mo copiktra
vs mo compar hr impress result
patient gener limit respons older therapeut
exhibit copiktra posit perform phase duo studi
relapsed/
cll/sll
duo led
review
respons
lymphoma
copiktra attain orr follicular lymphoma fl patient lead
toward potenti acceler approv final analysi
patient fl cohort dynamo copiktra overal respons rate orr
cr measur irc exhibit blue bar fl patient studi
rapid time respons median month durat
respons median progression-fre surviv month overal
surviv os month appear meaning result
patient refractori rituximab chemo/rit
ibrutinib appear effect given unmet need refractori
follicular lymphoma copiktra efficaci molecul receiv acceler
approv fda set septemb believ fl
patient could earli adopt copiktra therapi treatment option
limit relapsed/refractori fl set
exhibit copiktra posit perform dynamo waterfal plot
acceler approv
copiktra close transform verastem prioriti review underscor
potenti data duo dynamo support copiktra us licensur
septemb ahead octob pdufa date februari
verastem submit nda copiktra seek full approv molecul
relapsed/refractori follicular lymphoma fl copiktra nda accept
prioriti review establish octob pdufa june
copiktra licens yakult honsha rate develop
commerci japanes market licens geographi
double-
lymphoma
acceler
approv
set
note
duvelisib
coliti
rate
idelalisib
possibl copiktra evalu earlier line therapi cll fl
indic combin multipl agent begun see
initi posit data emerg expect work area beyond cll
fl copiktra also develop peripher t-cell lymphoma
anoth set materi unmet need molecul shown
promis activ earli clinic work us licensur expect interest
molecul materi increas public present
activ profil continu emerg
exhibit copiktra posit perform dynamo solid result
copiktra novel dual inhibit copiktra select target
delta gamma isoform phosphoinositid key
element central signal pathway involv cancer prolifer
surviv dual inhibit copiktra believ
directli attack malign b-cell t-cell also disrupt tumor
micro-environ specif nearli exclus express
hematopoiet cell hyperact b-cell malign promot
b-cell prolifer growth surviv adhes home
demonstr activ variou b-cell leukemia lymphoma
intriguingli also reduc immuno-suppress treg highli express
myeloid cell activ appear associ increas
stabil tumor microenviron inhibit appear abl
reshap tumor immun microenviron promot tumor regress
without target cancer cell directli result find
copiktra dual inhibit activ develop work consider
copiktra combin checkpoint inhibitor
separ sever toxic seen select
inhibitor manag copiktra clearli focu
verastem good complianc prophylaxi regimen manag
infect risk recent intens focu ae manag evolv
broader adopt io therapeut believ effect
address verastem addit cll kol believ copiktra
inhibit may materi decreas sever unpredict immun
mediat toxic coliti etc appear select
revenu
reach
us
across
time
built
market dynam cll fl provid materi room copiktra
importantli market dynam cll appear favor toward
accept copiktra later line therapi imbruvica ibrutinib move
toward front-lin consider materi number patient
experienc resist molecul toler issu
element creat room relapsed/refractori set
copiktra addit venclexta also approv refractori set
also signific challeng toler suffer
conveni issu hospit dose ramp week fl
rel lack efficaci agent later line provid materi
room copiktra initi indic relapsed/refractori cll/sll
fl copiktra potenti simpl oral monotherapi typic elderli
cancer patient believ result materi consider along
addit use cell tumor possibl other variou
combin cll/fl therapi even io therapeut copiktra
revenu potenti could ultim reach us peak across
indic row well
fak inhibitor defactinib progress verastem multipl studi
on-going evalu defactinib focal adhes kinas fak inhibitor
combin approv therapeut fak activ variou
tumor shown drive exhaust cell recruit
treg tumor microenviron among effect permit
enhanc growth fak-express tumor fak inhibit therefor
potenti creat favor tumor microenviron anti-canc
therapi checkpoint inhibitor verastem conduct phase trial
antibodi bavencio avelumab ovarian cancer
washington univers school medicin cancer research uk
conduct earli phase trial antibodi keytruda
pembrolizumab nsclc pancreat cancer mesothelioma
washington univers present encourag phase data defactinib
keytruda gemcitabin advanc cancer patient show pr
stabl diseas pancreat ductal carcinoma pdac patient
diseas control rate pdac support move tripl combin
pdac expans cohort recommend phase dose though earli
clinic set defactinib demonstr meaning proof-of-
concept program could establish materi potenti offer substanti
upsid vstm share
verastem corpor strategi capabl verastem cannili acquir
right copiktra infin pharmaceut attract econom
latter compani bit corpor pickl posit data readout
quit benefici verastem verastem prepar copiktra
upcom commerci launch commit market molecul
us partnership outsid us recent ink deal yakult
japan expect addit agreement eu asian
countri well approv us septemb
commerci verastem us commerci infrastructur recently-
appoint chief commerci offic joseph lobacki materi commerci
expertis prior experi launch xtandi chief commerci offic
mediv therapi well
verastem vstm share valuat verastem oper
potenti signific revenu earn variabl come
quarter year result valu oper use fully-tax risk-
weight net present valu methodolog major asset calcul
npv estim use vstm share million verastem two
advanc proprietari asset copiktra relaps refractori cll/sll
double-refractori fl defactinib earli phase studi solid tumor
repres bulk valu verastem oper view
copiktra approv relapsed/refractori cll/sll fl two
prior treatment emerg defactinib clinic proof-of-concept
activ oncolog sector on-going valu vstm share probabl
weight follow scenario verastem oper independ
verastem acquir larger particip biopharmaceut
scenario verastem oper independ assess total valu
verastem lead program asset per vstm share exhibit
assum verastem continu oper independ
copiktra valuat estim copiktra next-gener twice-
daili oral inhibitor approv fda verastem valuabl
asset believ materi potenti low-burden twice-daili oral
monotherapi market refractori patient look continu care
commun set cll fl indic estim peak us
revenu greater million copiktra across indic
million cll fl verastem direct clinic develop molecul
broaden label composit matter patent protect estim
potenti extens possibl beyond copiktra current
estim estim valu asset verastem
per vstm share use fully-tax risk-weight npv methodolog
consid addit assumpt verastem licens molecul
partner variou intern geographi addit model
million mileston payment infin pharmaceut upon copiktra
defactinib valuat defactinib demonstr potenti improv
tumor microenviron current evalu combin
solid tumor indic earli activ shown
pdac defactinib profil translat meaning clinic benefit
could signific potenti molecul solid tumor signific
upsid npv calcul high risk current valu
defactinib per vstm share
asset verastem net cash total million per vstm
share nol asset drag gener corpor oper
expens total per vstm share yield total
scenario verastem valuat take-over chang basic
oper assumpt valu verastem take-over scenario includ
flow full copiktra econom potenti suitor exclud japan asia
eu assum verastem engag licens agreement
result royalti take-over scenario also includ less increas
 materi less sg expens sinc scale effici would
like gain suitor addit increment capac could
leverag expand potenti applic copiktra take-over
calcul collect yield npv copiktra suitor
addit chang scenario includ corpor effici gain
take-over corpor drag reduc improv potenti broader
defactinib develop program inclus chang control
premium primari asset compani copiktra
defactinib off-set bit use fulli dilut share addit
calcul base commerci launch copiktra demonstr
adopt first year lead toward improv probabl success
broad commerci uptak collect take-over valuat result
npv per fulli dilut vstm share exhibit sinc project
discount take-over npv present day per
annum result npv per fulli dilut vstm share
probabl weight scenario lead
probabl weight two scenario assign probabl verastem
oper independ buy-out anoth entiti use
weight deriv overal probability-weight npv
underpin price target per vstm share
verastem asset npvaluenpv/shareduvelisib first second credit control prem compani
copiktra licens infin pharmaceut copiktra verastem
registration-stag oral dual inhibitor isoform delta gamma
licens infin pharmaceut intellikin divis takeda
tkppi rate along asset
announc close ipo million share common stock
per share aggreg net proce approxim million
fund continu develop earli stage therapeut companion
juli verastem licens defactinib verastem enter
exclus licens agreement research develop manufactur
defactinib therapeut diagnost
prophylact use human fak inhibitor thought block
transcript chemokin recruit regulatori cell creat
up-front issu common share elig
million development mileston addit million
regulatori sale mileston high-singl mid double-digit royalti
futur net sale
licens infin pharmaceuticalsinfin licens duvelisib profit share ipo rais develop cancer stem licens defactinib assetsasset initi target achiev posit phase volunteerssupport develop duo studi duvelisib r/r cll/sll initiatesdata basi nda licens oncolog up-front mileston us profit registration-direct studi terminatescommand trial mesothelioma stop fulli enrol phase dynamo studi nhlorr data support acceler approv initi corpor restructuringreduc headcount reciev fda track r/r cll fl track facilit develop interact miss phase autoimmun studiesdevelop pivot sole oncolog initi io collaborationsevalu ovarian pancreat cancersvvvsep temin duvelisib collaborationright return infi paid totalvvvvnov in-licens duvelisib infiphas asset mileston royaltyvvvvvdec dynamo data oral present demonstr meaning orr acceler appov vvvvvjun long-term follow-up data icml ehaimprov orr in-lin safeti grant fda track r/r track facilit develop interact w/fdavvvvoct guidanc duvelisib nda submissioninform nda submiss strategyvvvvdec phase duo data oral present irc manag safeti profil support ndavvvvvdec phase data tcl oral present support developmentvvvvdec equiti financingproce fund precommerci effortsvvvvjan hercul debt facil addit fundingvvvvfeb nda submittedseek full approv r/r cll/sll acceler approv fl vvvvfeb phase result publish bloodpubl drive awar medic initi phase brio studyenrol btk-experienc cll/sll initi phase primo studyenrol r/r pt posit data expand labelvvvapr nda accept prioriti reviewvalid potenti duvelisib address unmet needvvvvvjun present abstract ascoaddit duvelisib data defactinib/keytruda pancreaticvvvvjun partner up-front mileston double-digit royaltiesvvvvjun eha meetingor present earli cll biomark equiti capit offer atm fund pre-commerci activitiesvvvv signific least import vvvvv import
copiktra phase result phase safeti data healthi subject
present medic confer copiktra singl dose
multipl dose twice
daili daili assess copiktra pharmacokinet dose-
depend achiev concentr suffici potenti
inhibit dose copiktra safeti line placebo
verastem rais million juli verastem announc
close million share common stock total net
proce million fund defactinib clinic develop
phase duo trial initi relapsed/refractori chronic
phase duo trial enrol relapsed/refractori cll/sll patient receiv
either twice daili oral copiktra dose continu iv ofatumumab
standard-of care iv day iv weekli week
monthli month crossov trial design allow patient progress
either arm cross patient requir receiv
pneumocysti prophylaxi cmv prophylaxi recommend
primari endpoint secondari endpoint includ orr durat
respons os safeti also evalu elig requir prior anti-
cancer therapi hemoglobin least platelet count
higher independ transfus support minimum absolut
neutrophil count patient prior btk inhibitor exclud
posit data present oral present
copiktra licens oncolog use copiktra
licens
infin rate develop
commerci oncolog use term million up-front
addit million mileston us profit share royalti
intern sale made total payment infin million
termin agreement septemb
price million common share per share aggreg net
proce approxim million fund defactinib clinic program
includ registration-direct command studi mesothelioma
phase trial patient kras-mut nsclc
aug copiktra grant fda track design relapsed/
refractori cll track design facilit develop drug
treat seriou condit fill unmet medic need design
help facilit verastem interact agenc may help
expedit on-going nda review process copiktra fda ema orphan
drug design indic
sep defactinib command studi stop due futil verastem
termin defactinib command trial malign pleural mesothelioma
due differ defactinib versu placebo popul
patient merlin-low tumor registration-direct random
double-blind placebo-control command studi evalu defactinib
switch mainten treatment patient malign pleural
mesothelioma benefit frontlin therapi
sep public highlight posit effect fak inhibit
tumor micro environ preclin studi publish cell show
activ fak accumul nucleu tumor cell promot immun
escap fak facilit transcript chemokin cytokin
encourag develop
environ data support assess fak
combin cell stimulatori therapeut
copiktra dynamo studi complet enrol indol non-
continu treatment double-refractori indol nhl refractori
rituximab chemotherapi radioimmunotherapi patient
follicular lymphoma fl small lymphocyt lymphoma sll
margin zone lymphoma mzl elig restrict
cytopenia primari endpoint best orr secondari endpoint
includ durat respons os safeti posit data
present oral present strengthen long-term
follow-up data present oral present
confer malign lymphoma icml eha meet
oct verastem corpor restructur wake defactinib
command trial verastem reduc headcount full time
copiktra grant fda track design double-
refractori follicular lymphoma fl follicular lymphoma materi
patient subset dynamo studi track design facilit
develop drug treat seriou condit fill unmet medic
need design help facilit verastem interact
agenc may help expedit on-going nda review process copiktra
fda ema orphan drug design indic
copiktra miss autoimmun indic transit focu
oncolog phase aspira studi copiktra
twice-daili plu methotrex week improv primari
endpoint versu placebo rheumatoid arthriti addit
copiktra twice daili day improv
phase allergen challeng studi patient mild asthma copiktra
develop focu oncolog indic
defactinib io collabor bavencio ovarian cancer
phase trial evalu defactinib combin pfizer/merck kgaa
antibodi bavencio avelumab patient relapsed/refractori
ovarian cancer dose-escal portion enrol patient
determin recommend phase dose expans portion treat
patient phase dose primari endpoint safeti maximum
toler dose orr part surviv immune-bas respons metric
secondari endpoint accord clinicaltri gov full studi complet
washington univers initi phase trial defactinib
keytruda gemcitabin pancreat cancer investigator-initi
phase dose-escal studi enrol patient advanc
pancreat cancer primari endpoint recommend phase dose
secondari outcom safeti anti-tumor efficaci measur full
studi complet expect juli accord clinicaltri gov
preliminari data present see
turn pancreat cancer checkpoint immunotherapi
preclin studi publish jiang et al natur medicin conclud fak
inhibit may
import combin strategi checkpoint
inhibitor studi demonstr fak signal contribut fibrot
immun suppress tumor microenviron neoplast pancreat
ductal adenocarcinoma pdac cell fak inhibit
increas immun surveil pdac tumor alter product
pro-inflammatori immunosuppress cytokin make tumor
respons immunotherapi
sep abbvi termin copiktra collabor return right
infin multipl collabor includ purchas
pharmacycl ibrutinib imbruvica consider use front-
line cll partnership roch rhhbi rate venclexta
caus conflict ring fenc around collabor notifi
infin termin copiktra collabor june top-
line data dynamo abbvie/infin agreement formal end
septemb year
verastem grab copiktra oncolog infin infin
perhap unprepar return copiktra burden materi
on-going infin look partner copiktra short time
complet transact verastem enter agreement infin
licens copiktra includ exclus world-wide right research
develop commerci manufactur copiktra-bas product
oncolog indic verastem paid infin million cash upon posit
phase data duo trial pay million cash stock
approv copiktra us intern verastem pay tier
mid-to-high single-digit royalti infin royalti infin cover
legaci agreement compound mundipharma privat
dec dynamo oral present verastem present
primari analysi phase dynamo studi oral present
follicular lymphoma fl cohort total serv basi
on-going nda review acceler approv double-refractori fl
patient orr includ orr fl patient pr
independ review meet primari endpoint orr
less evalu patient target lymph node reduct
independ review overal studi median durat respons
month respect independ review copiktra
consid well toler manag safeti profil presenc
appropri risk mitig accord flinn et al
dec contempo present preliminari data
phase contempo trial copiktra plu rituximab dr obinutuzumab
untreat fl patient present best orr
assess investig dr arm cr
arm cr safeti profil dr
consist previous character safeti copiktra monotherapi
accord casulo et al enrol onto studi
termin earli copiktra develop follicular lymphoma remain
focus double-refractori popul
data double-refractori follicular lymphoma verastem present long-
term follow-up data fl subset data dynamo oral
present icml eha meet comment gener relat
fl cohort orr fl patient improv includ cr
independ review investig assess median
durat respons month respect independ
review respons observ rapidli within median month
patient copiktra median month median os
month zinzani et al conclud copiktra remain well toler
demonstr favor benefit/risk profil double-refractori fl
copiktra grant fda track design peripher t-cell
lymphoma verastem initi phase studi copiktra assess
molecul efficaci safeti see track
design facilit develop drug treat seriou condit
fill unmet medic need design help facilit
verastem interact agenc design may help expedit
review process
defactinib phase combin keytruda launch cancer
research unit kingdom investigator-sponsor studi evalu
defactinib plu keytruda merck rate antibodi
patient refractori nsclc pancreat cancer mesothelioma
comer phase portion enrol cohort patient
expans cohort nsclc pancreat cancer mesothelioma enrol
patient pre-specified futil analys primari endpoint
safeti secondari outcom includ efficaci pk assess primari
complet expect may accord clinicaltri gov
sep verastem announc posit top line result phase
duo studi cll/sll posit top line data random
patient phase duo studi relapsed/refractori cll/sll demonstr
median month copiktra significantli greater
month ofatumumab hr blind independ
review committe key subpopul patient difficult treat
delet patient median vs month copiktra
oct fda provid construct guidanc copiktra regulatori
pathway verastem met fda receiv written feedback regard
copiktra nda strategi base guidanc verastem nda request full
approv copiktra treatment relapsed/refractori cll/sll
acceler approv treatment patient relapsed/refractori fl
dec copiktra phase duo data get oral present
american societi hematolog meet posit data
random phase duo studi relapsed/refractori cll/sll
discuss oral present signal
signific new treatment option later line cll patient patient
progress ofatumumab cross receiv copiktra
cross copiktra ofatumumab trial posit
primari endpoint see orr copiktra
ofatumumab per independ review copiktra patient
decreas lymph node burden baselin compar
treat ofatumumab
appear manag consist seen prior data
accord kol import consider copiktra potenti use
commun set given oral dose
dec copiktra phase combin data relapsed/refractori t-cell
lymphoma oral present investig memori sloan
ketter present result parallel dose-escal phase trial
evalu copiktra either romidepsin bortezomib relapsed/
refractori peripher cutan ctcl t-cell lymphoma
regimen achiev respons rate least
limit dose escal bortezomib
romidepsin evalu copiktra plu romidepsin plan
announc price million common share per share
aggreg net proce approxim million fund commerci
prepar launch cost copiktra
jan verastem increas debt facil million verastem
increas exist loan agreement hercul capit provid
million support regulatori commerci activ
copiktra on-going develop million remain avail
drawn upon sever tranch upon fda accept copiktra nda
condit
jan preclin data support copiktra io combin asco-
clinic immuno-oncolog symposium verastem patcher
weaver present preclin data support potenti copiktra
combin therapi co-stimulatori antibodi patient
 cell malign copiktra clinic activ monotherapi cell
malign addit inhibit known reduc immune-
suppress treg inhibit known reduc immunosuppress
efficaci checkpoint co-stimulatori antibodi anti-
antibodi support work io combin
patient cell malign well tumor type
feb copiktra nda submit verastem file copiktra nda full
approv copiktra treatment relaps refractori cll/sll
acceler approv treatment relapsed/refractori fl
advanc
hematolog malign publish blood open-label dose-
escal phase trial flinn et al evalu maximum toler dose
pharmacodynam respons efficaci safeti copiktra
patient advanc hematolog malign includ patient
dose-escal receiv twice daili patient
expans phase copiktra dose bid continu
studi identifi twice daili copiktra rapidli absorb
show dose-depend pharmacokinet profil safeti data inform
public underscor copiktra potenti cll/sll provid solid
evid support on-going nda tcl subset publish
horowitz et al support addit phase primo studi
initi copiktra phase brio studi cll/sll patient
evalu copiktra patient cll/sll relaps
refractori intoler prior btk therapi ibrutinib primari
endpoint orr secondari endpoint includ safeti durat respons
diseas control rate primari analysi expect june
accord clinicaltri gov posit expect data support
increas adopt patient follow btk therapi
initi copiktra phase primo studi peripher t-cell
primo studi evalu copiktra twice daili determin
optim dose relapsed/refractori peripher t-cell lymphoma
patient divers group aggress non-hodgkin lymphoma
dose select patient enrol onto expans phase
primari endpoint orr secondari endpoint includ safeti durat
respons diseas control rate os primari analysi expect
around novemb accord clinicaltri gov posit data could
support expand copiktra label
initi phase rockif studi defactinib carboplatin-
resist ovarian cancer univers san diego phase rockif trial
evalu defactinib re-sensit carboplatin-resist ovarian cancer
carboplatin paclitaxel single-arm trial enrol patient assess
safeti orr combin estim primari complet
septemb full studi complet anticip octob
accord clinicaltri gov view continu investig interest
defactinib combin trial support propos underli biolog
april copiktra nda accept fda prioriti review verastem
announc fda accept verastem copiktra nda april
establish octob pdufa action date fda accept copiktra
nda allow verastem begin materi ramp pre-commerci
june verastem present abstract copiktra
defactinib american societi clinic oncolog meet
june verastem present five poster focus copiktra defactinib
data highlight benefici effect copiktra dual inhibit
tumor microenviron suggest earli sign activ
pancreat cancer
june copiktra partner yakult honsha co ltd japan
exclus licens agreement give yakult right copiktra oncolog
indic japan verastem receiv million up-front elig
million develop commerci mileston double-digit
royalti yakult also fund certain global develop cost copiktra
pro-rata basi partnership add level industri valid
previous describ data set present prioriti review
june verastem rais million verastem close regist sale
million share common stock per share conson
capit net proce offer approxim million help
fund pre-commerci copiktra
june copiktra show activ front line cll combo
european hematolog associ meet dr mathew david dana-
farber cancer institut present data investigator-sponsor trial
evalu potenti addit copiktra increas cure rate
fcr fludarabin cyclophosphamid rituximab frontlin set
younger cll patient high rate bone marrow mrd minimum residu
diseas neg achiev better histor fcr cohort
compar ibrutinib/fcr data accord investig high rate
bone marrow mrd neg achiev patient unmut ighv
associ poor prognosi fcr addit respons deepen
copiktra mainten follow complet fcr combin
toxic appear materi manag event compar either
agent alon accord david et al includ infecti immune-
mediat event well secondari malign conclus
dfcr effect regimen younger fit patient may desir chanc
long term remiss
exhibit verastem recent import upcom event
dateeventcommentsignificancesep duvelisib approv fdaverastem posit rapidli launch w/ duvelisib ou partnershipaddit effort china other modest clinic proof-of-conceptposit data support expans effort maashould acceler partnership eu partnershippotenti materi upfrontsvvvv signific least import vvvvv import
septemb copiktra receiv fda approv cll/sll fl
fda approv copiktra ahead octob pdufa date trigger
million mileston payment infin payabl either cash stock drug
indic twice-daili treatment relapsed/refractori cll/sll
patient fail two prior line therapi relapsed/refractori fl
patient fail least two prior line therapi verastem pois
commerci copiktra presenc sale rep district manag
market access profession medic scienc liaison view copiktra
conveni highly-act twice-daili oral therapi relapsed/refractori
cll/sll fl potenti indic peak us sale exceed
million cll/sll fl possibl exceed million includ
use
addit copiktra partnership addit
june japan partnership yakult like addit
geographi verastem seek partner copiktra retain
materi econom addit partnership asia possibl addit
upfront mileston verastem potenti add addit non-
dilut capit verastem transit commerci entiti would
expect potenti partner becom aggress fda
addit copiktra combin studi addit june
eha data copiktra fcr fludarabin cyclophosphamid
rituximab frontlin set younger cll patient would expect
addit studi data public copiktra variou combin
regimen multipl addit set instanc dr mathew david
dana-farb cancer institut plan begin enrol phase trial
assess combin copiktra/venclexta
relapsed/refractori cll/sll patient copiktra dose one week
venclexta ad primari endpoint trial dose
combin rate complet remiss studi enrol patient
prior exposur either agent
proof-of-concept defactinib io combin
sever on-going studi evalu defactinib combin io antibodi
bavencio keytruda verastem conduct phase trial
bavencio ovarian cancer washington univers school
medicin cancer research unit kingdom conduct earli phase
trial keytruda advanc nsclc pancreat cancer
mesothelioma all-com phase data trial washington
univers evalu defactinib plu keytruda gemcitabin present
support expans pdac cohort
duvelisib file eu verastem expect submit dossier
european approv duvelisib ema anticip eu
approv file could potenti acceler eu partner effort
verastem summari verastem focus develop cancer
therapeut advanc program copiktra defactinib
progress clinic studi multipl indic set copiktra
verastem materi asset first-in-class molecul licens
late infin target delta gamma
isoform phosphoinositid pathway central signal
pathway one frequent dysregul cancer prolifer
surviv dual inhibit delta gamma isoform
copiktra directli attack malign b-cell t-cell believ
materi disrupt tumor microenviron
flinn et al dynamo phase studi copiktra patient refractori indol non-hodgkin
copiktra gener posit data relapsed/refractori chronic lymphocyt
leukemia small lymphocyt lymphoma cll/sll third-lin follicular
lymphoma fl nda approv fda septemb treatment
relapsed/refractori cll/sll least two prior therapi
relapsed/refractori fl least prior system therapi copiktra
undergo us commerci launch expect bulk near-term investor
interest focu program oral bioavail materi
unmet need relapsed/refractori set use set
repres upsid estim copiktra us revenu could exceed
million peak verastem intern royalti mileston revenu
copiktra also expect contribut oper
defactinib fak inhibitor also evalu combin
approv io therapeut fak activ shown drive
exhaust cell recruit treg
tumor
microenviron among effect permit growth fak-express
tumor fak inhibit defactinib therefor potenti creat
favor microenviron cell focus anti-cancer therapi
checkpoint inhibitor
biolog brief phosphatidylinositol famili
intracellular lipid kinas gener second messeng regul sever
downstream pathway critic normal cell growth prolifer
metabol addit diseas enzym major posit
major neg regul pathway regul
growth surviv prolifer exhibit famili divid
class ii depend upon code gene structur substrat
prefer class four member character accord
activ model class ia consist class ib
consist class ia heterodim consist
regulatori subunit catalyt subunit class ib compris
singl catalyt subunit associ regulatori
subunit wherea isoform show broad tissu distribut
highli express leukocyt control immun respons exhibit
among class studi
fundament physiolog patholog role
exhibit copiktra inhibit differenti
implic
import signal compon frequent
mutat protein human cancer often result unregul
signal activ tumorigenesi ann pathol
malign curr opin pharma activ
pathogenesi malign
develop resist anti-cancer therapi inhibitor
consider promis therapi combin cytotox
biolog therapi well though remain fulli elucid
therapeut strategi focus modul pathway
potenti develop util biomark patient-specif mutat
profil maxim benefit combin import
complex signal make challeng target develop
cancer therapeut
preclin studi suggest specif pathway inhibitor may
imped tumor cell growth and/or induc apoptosi combin
pathway inhibitor chemotherapi attenu resist
pathway implic wide varieti respons
inhibit induc antitumor effect molecul design target specif
compon pathway develop clinic use singl
agent combin cytotox drug variou tumor type
addit character activ select inhibit isoform
demonstr promis
microenviron creat potenti
develop molecul
exhibit signal pathway target cell
term modul
focu copiktra dual inhibit copiktra
believ directli attack malign b-cell t-cell also disrupt
tumor microenviron nearli exclus express
hematopoiet cell hyperact cell malign promot b-
cell prolifer growth surviv adhes home
locat
downstream variou b-cell receptor includ cell antigen receptor
bcr cytokine/chemokin receptor adhes molecul exhibit
pathway orchestr activ b-cell malign
upon bcr activ therefor demonstr activ
variou b-cell leukemia lymphoma intriguingli recent work
describ ali et al natur inhibit also shown
exhibit multipl role tumor growth surviv
david md mmsc et al phase ib/ii studi copiktra combin fcr dfcr frontlin
therapi younger cll patient
lead express
focu copiktra highli express myeloid cell
activ appear associ increas stabil tumor
microenviron activ restrain nfb activ promot
suppress factor tumor growth work keneda et al de henau
publish natur depict exhibit show effect
inhibit tumor immun suppress inhibit inhibit c/ebp
stimul nfb lead alter express pro-inflammatori immun
pro-inflammatori macrophag promot cell respons
suppress tumor growth sum inhibit appear abl
reshap tumor immun microenviron promot tumor regress
collect featur inhibit copiktra
summar work conduct verastem present asco-sitc
addit proven activ monotherapi patient cell
malign copiktra activ tumor microenviron result
greatli enhanc efficaci antibodi induc tumor
regress immun memori combin immune-oncolog
approach lymphoma model support explor
molecul io combin
exhibit gamma inhibit activ convert tumor associ macrophag pro-inflammatori
macrophag suppress tumor growth
keneda et al molecular switch control immun suppress natur
copiktra basic copiktra twice-daili oral phosphoinositid
delta gamma enzym inhibitor copiktra first-in-class
investig dual inhibitor delta gamma isoform
enzym known help support growth surviv malign b-
cell t-cell signal may lead prolifer malign b-
t-cell thought play role format mainten
tumor microenviron molecul current fda review
treatment relapsed/refractori chronic lymphocyt leukemia small
lymphoma cll/sll relapsed/refractori follicular
lymphoma fl base posit result phase duo phase
dynamo trial respect receiv prioriti review fda
pdufa date octob phase develop program peripher t-
cell lymphoma on-going molecul well copiktra inhibit
signal pathway effect direct anti-canc effect
malign b-cell via isoform inhibit benefici anti-canc
effect tumor microenviron via inhibit copiktra fda
track design indic review
orphan drug design cll/sll us europ
exhibit copiktra delta gamma inhibit activ
 pacher weaver dual inhibitor copiktra reduc immunosuppress treg myeloid cell enhanc efficaci
checkpoint co-stimulatori antibodi cell lymphoma model asco-sitc clinic immuno-oncolog symposium
escal phase trial flinn et al evalu maximum toler dose
pharmacodynam respons efficaci safeti copiktra
patient advanc hematolog malign patient dose-
escal twice daili patient expans phase
twice daili continu studi identifi
twice daili copiktra rapidli absorb show dose-depend
pharmacokinet profil maxim p-akt suppress achiev
twice daili safeti data inform phase duo protocol
includ mandatori pneumocysti prophylaxi dose
patient discontinu treatment toxic versu
copiktra cll
lymphocyt leukemia cll common adult leukemia
western hemispher estim patient diagnos
us accord american cancer societi diseas primarili
affect elderli median age diagnosi year burger et al
nejm time first treatment year diagnosi itachaki et al ther
adv hematol cll highli heterogen malign broad cours
develop caus accumul matur abnorm cell
bone marrow cell divid faster surviv longer normal cell
cll cell move blood stream organ
lymph node spleen either fulli partial block product
normal blood cell lead anemia neutropenia thrombocytopenia
primari differ cll sll cll
malign cell blood bone marrow wherea sll cancer cell
lymph node
cll associ sever unfavor genom molecular alter
patient delet mutat wors prognosi
alter affect treatment decis major newli diagnos
patient asymptomat monitor symptom onset
lymphadenopathi bone marrow failur note worsen anemia
thrombocytopenia symptom often complic chronic
comorbid hypertens arrhythmia renal insuffici other
time treatment initi barriento cancer control
exhibit suggest algorithm initi cll
 barriento sequenc chronic lymphocyt leukemia therapi hematolog
cll treatment paradigm vari newli diagnos asymptomat patient
put watch wait approach current treatment option
cur earli treatment associ improv surviv
barriento hematolog allogen stem cell transplant cur
gener inappropri given averag age cll diagnosi
year accord american cancer societi pharmacolog intervent
launch symptom onset therapeut select gener depend
delet mutat statu patient overal fit
select appropri regimen remain challeng clinician barriento
rituximab br fludarabine/cyclophosphamide/rituximab fcr
imbruvica ibrutinib primari consider patient
younger fit elderli patient
imbruvica lean difficult popul includ delet
expect imbruvica continu greater util first-lin set
btk move broad use first line cll present
opportun later line bruton tyrosin kinas btk inhibitor
move forward cll/sll treatment paradigm broadli base improv
efficaci across poor prognost factor safeti better cytopenia infect
profil patient qualiti life oral br fcr itachaki et al ther
adv hemato johnson johnson review
imbruvica approv once-daili treatment cll/sll without
delet includ front-lin indic march base data
trial across sever indic report global
imbruvica revenu billion addit calquenc acalabrutinib
astrazeneca azn rate select btk inhibitor look
potenti differenti toler potenti better atrial fibril
discontinu profil approv octob twice-daili
treatment relaps mantel cell lymphoma on-going phase work cll
other calquenc report sale million initi front-lin
adopt elderli poor prognost factor expect
result phase trial evalu imbruvica /- rituximab vs fcr
younger br older patient
complet defin role btk inhibitor first-lin cll
ibrutinib activ yet challeng cll despit remark rate partial
respons drive util cll even challeng delet
patient mani discontinu ibrutinib depend upon length
time examin haematologica toxic main reason
discontinu though mani discontinu due diseas progress well
partial respons rate high though complet respons
follow treatment nave patient previous treat
cll patient blood jama oncolog ibrutinib
metabol concomit use inhibitor induc
profound effect serum ibrutinib level low grade sever
bleed seen drug materi incid atrial
fibril afib hypertens grade month sever
infect hematolog complic diarrhea rash
among other ibrutinib inhibit kinas btk quit potent
may explain toxic exampl kinas target
ibrutinib includ induc kinas itk t-cell thu
growth factor receptor egfr perhap contribut skin gi toxic
tec famili protein potenti reason bleed diathesi
materi unmet need btk intoler non-respond patient
phase trial imbruvica treatment-nav cll patient
publish new england journal medicin burger et al rate
treatment discontinu due patient median
imbruvica exposur month howev real world experi suggest
rate discontinu owe toxic substanti higher analysi
mato et al cll patient show first-lin
relaps patient discontinu due notabl front-
line discontinu due atrial fibril reason
discontinu infect hematolog toxic bleed imbruvica
uniqu toxic profil expect becom increasingli signific
compon patient manag use continu broaden itachaki et
exist second-lin cll option leav open copiktra oral
monotherapi profil current commonli use therapeut
post-front line set gilead rate zydelig inhibitor
abbvi venclexta barriento hematolog believ
option materi commerci limit creat open
efficaci all-or agent safeti profil manag
commun set view zydelig idelalisib oral agent
approv cll use combin iv rituximab dose bi-weekli
dose monthli multipl black warn fatal
seriou toxic hepat patient sever diarrhea coliti
pneumon infect intestin perfor
march fda issu drug safeti alert ema start review
drug due rate seriou advers event includ death clinic
trial zydelig combin lead gilead halt clinic trial includ
sever phase effort line cll nhl sae interest
molecul relat pjp cmv infect despit death occur
pjp prophylaxi regimen administ seriou
led gilead pull back market effort zydelig revenu
wane gilead report zydelig revenu million
appear materi support drug commerci
believ move gilead provid room anoth focus oncolog
player particip meaning refractori set
exhibit willing cll patient undergo lt therapi
cll societi reader poll cll tribun
venclexta venetoclax inhibitor fda approv relapsed/refractori
cll delet april recent combin
rituximab relapsed/refractori cll though venclexta venetoclax oral
drug lengthi oner titrat regimen establish due
risk tumor-lysi syndrom tl retrospect analysi real-world
patient conduct mato et al venclexta titrat period
patient achiev fda recommend dose daili nearli
patient receiv tl prophylaxi receiv rasburicas
patient least one plan hospit stay monitor
break-out venclexta sale believ potenti commerci
profil copiktra would offer materi improv twice-daili all-
oral treatment low pill burden observ food effect
approv believ potenti offer improv patient
quality-of-lif patient care compar exist approv agent
travel materi burden achiev adequ accord
cancer support commun access cancer barrier
challeng survey patient list lack transport list
could get child/adult care list could get time work
primari reason get recommend care multipl respons
allow data highlight need conveni all-or approach
ensur patient receiv adequ care view
exhibit phase duo studi design refractori cll/sll patient
data copiktra demonstr signific improv
phase duo trial duo phase trial enrol patient relaps
refractori cll/sll compar copiktra twice-daili ofatumumab
iv infus regim describ exhibit note oral
present copiktra demonstr median month
significantli greater month ofatumumab hr
 assess blind independ review committe exhibit
 left overal surviv popul similar treatment
arm hr expect in-lin prior approv
cll base believ benefit support approv
copiktra set
exhibit copiktra increas overal popul left delet subset right
data copiktra efficaci challeng delet popul
key subpopul patient delet respond well
tradit cll therapeut respond moder well newer
therapeut copiktra demonstr median month vs
month ofatumumab hr exhibit right suggest
copiktra util may appropri patient poor
prognosi consid robust respons challeng subset
delet patient indic robust activ copiktra cll
duvelisib data copiktra signific improv orr phase use
investig assess median vs month
overal popul potenti better proxi overal patient
benefit rather irc analysi orr copiktra
ofatumumab per irc exhibit saw
copiktra orr benefit maintain across delet subset
orr vs per irc addit copiktra patient
decreas lymph node burden baselin compar
treat ofatumumab duo studi multipl subpopul
assess materi favor copiktra studi exhibit
manag copiktra safeti profil duo appear manag accord
kol materi import consider potenti use
commun set given oral dose note median exposur
week copiktra versu week ofatumumab due crossov design
significantli better efficaci observ copiktra arm approxim
patient remain copiktra month patient
requir pneumocysti prophylaxi cmv prophylaxi
recommend grade higher event copiktra versu ofatumumab
includ neutropenia patient vs diarrhea vs
pneumonia vs anemia vs coliti vs
exhibit copiktra safeti profil duo trial
brown
cll center
note
duvelisib
coliti
rate
idelalisib
safety/toler modest discontinu importantli
class advers event frequent lead discontinu diarrhea
transaminas elev rash overal rate discontinu
due rate sever opportunist infect
includ patient pneumocysti jirovecii pneumonia pjp protocol
mandat prophylaxi patient cmv coliti patient
bronchopulmonari aspergillosi fungal infect four treatment-
relat led death copiktra due staphylococc pneumonia
sepsi gener health deterior
exhibit copiktra discontinu due
exhibit copiktra maintain rel consist manag
safeti profil across multipl studi dose
flinn et al copiktra novel oral dual inhibitor clinic activ advanc hematolog
copiktra inhibit may also provid ae differenti
notabl kol jennif brown md phd associ professor
medicin harvard medic school director cll center
divis hematolog malign dana-farb cancer
comment recent analyst day present verastem copiktra
inhibit may actual decreas immun mediat
toxic appear unpredict idelalisib seen
much less coliti idelalisib discontinu rate
copiktra clearli differ significantli lower attribut
differ dual inhibit inhibit activ molecul
work character see
exhibit copiktra market model relapsed/refractori cll/sll
oral present suggest kol interest copiktra posit
data random phase duo studi relapsed/
refractori cll/sll present oral present
signal interest new treatment option later line cll patient per
protocol patient crossed-ov ofatumumab copiktra monotherapi
follow confirm progress copiktra activ substanti
new cll treat treated- average treatment durat month therapy- price/month launch us revenu
patient orr median durat respons month
median month investig assess larg in-lin
molecul gener result view
copiktra posit estim price cll/sll verastem full
approv copiktra treatment relapsed/refractori cll/sll
line therapi note approv therapi
approv meaning shortcom current estim
copiktra price approxim per month us
annual basi modest price increas per year copiktra oral
monotherapi activ potenti manag safeti profil
commun set could wide consid time treatment
relapsed/refractori cll/sll especi physician patient
copiktra opportunity/econom cll/sll though cll preval
estim us current recogn
patient diagnos annual take cautiou view regard adopt
trajectori expect initi use focus later line patient fewer
option accord verastem cll patient receiv second-lin
therapi patient receiv third-lin therapi
year physician becom comfort copiktra profil
prophylaxi regimen may opportun copiktra captur
materi share competitor given success random control
phase studi manag safeti profil oral monotherapi regimen well
unmet need set estim opportun copiktra
relapsed/refractori cll/sll assum util approxim
patient us similar number eu/row though latter
region lower price us assum patient receiv month
therapi averag peak util could reach million
world-wide approxim million us exhibit effici
 us royalti royalty- total approv japan upfront- china eu upfront- total revenu verastem expens cog us royalti royalti cog total net rate tax effect total per valu npv/share
gain captur via corpor infrastructur market
copiktra multipl indic similar call point rel low risk
given prioriti review estim fulli tax risk-weight npv
copiktra cll/sll share exhibit
exhibit copiktra fcr efficaci frontlin cll
david et al phase ib/ii studi copiktra combin fcr dfcr frontlin therapi
copiktra/fcr frontlin cll data phase investigator-
sponsor studi copiktra plu fcr fludarabin cyclophosphamid
rituximab treatment younger treatment-nav cll patient
present oral present eha studi conduct
dana-farb assess cycl combin copiktra
monotherapi mainten year primari endpoint rate cr
bone marrow mrd neg month follow complet fcr
rate primari endpoint success exhibit addit
patient primari analysi pr bone marrow neg
respons deepen copiktra monotherapi best respons bone
marrow mrd neg compar favor fcr histor
data compar ibrutinib/fcr data present
best rate abstract accord investig bone marrow
neg observ patient ighv mutat ighv
unmut subtyp less respons standard chemotherapi diseas
patient complet full year copiktra mainten includ
remain progress free median month sinc studi start
overal median follow-up month os
david et al phase ib/ii studi copiktra combin fcr dfcr frontlin therapi
 saespneumonia includ case pjp despit prophylaxisgrad febril neutopenia sinus zoster cmv rash aiha secondari malign grade metastat melanoma month post-fcr duvelisib grade glioblastoma multiform within month post-duvelisib mainten grade md within month post-duvelisib mainten duvelisib/fcr safeti overview
copiktra fcr safeti analysi patient receiv median cycl
combin regimen recommend phase dose copiktra
bid given fcr dlt observ grade febril neutropenia
copiktra qd rate grade infect
receiv steroid manag toxic overal patient requir dose
reduct chemo copiktra addit detail
combin safeti profil present exhibit investig
conclud copiktra/fcr toxic compar either monotherapi
includ infecti immune-medi event secondari malign
zydelig activ btk-experienc patient provid confid
copiktra copiktra explicitli studi btk-experienc
patient confid activ zydelig demonstr
materi activ set offer clinic proof-of-concept
mechan activ btk-experienc cll world treatment
experi publish mato et al blood demonstr
sequenc imbruvica zydelig achiev orr addit
patient achiev stabl diseas respons gener better
patient intoler prior therapi compar
diseas progress paradigm copiktra flush
on-going phase brio studi result expect
addit cll work copiktra potenti upcom approv
copiktra verastem expect widen consider copiktra
addit company-sponsor investigator-sponsor clinic
trial addit lymphoma popul part combin regimen
verastem leverag investig interest copiktra investigator-
initi trial name-brand institut sarah cannon institut
evalu copiktra combin rituximab bendamustine/rituximab
relapsed/refractori cll/nhl
copiktra venclexta investigator-sponsor trial relapsed/refractori
cll/sll dr mathew david dana-farb cancer institut plan begin
enrol phase trial assess combin
copiktra/venclexta relapsed/refractori cll/sll patient copiktra
dose one week venclexta ad primari endpoint
trial dose combin rate complet remiss
studi enrol patient prior exposur either agent
copiktra follicular lymphoma
follicular lymphoma background/summari follicular lymphoma fl
gener slow-grow form non-hodgkin lymphoma nhl cell
lymphoma typic occur later life averag age fl patient
year accord american cancer societi fl primarili occur
lymph node site bone marrow lead lymph node
swell loss appetit fatigu short breath achi given
slow-grow natur diseas symptomat patient
advanc diseas diagnosi leukemia foundat rare case
annual casulo et al blood fl transform aggress
diffus larg b-cell lymphoma dlbcl fl heterogen diseas
clinic prognosi impact sever factor age year elev
microglobulin hemoglobin bone marrow involv
lymph node diamet indol natur diseas lead long
median os year kahl et al blood accord
american cancer societi estim new nhl
case fl
rituximab
opportun copiktra watch wait approach gener appli
newli diagnos fl patient asymptomat patient local
diseas may amen radiotherapi patient advanc diseas
immunotherapi regimen recommend provid later-lin
therapi glaznik et al blood treatment select driven tumor
burden patient age comorbid
agent acceler approv double-refractori fl zydelig/idelalisib
molecul toler challeng aliqopa/copanlisib iv profil
limit remain limit consensu best cours patient
manag exhibit second- line later therapeut select driven
sever factor includ prior treatment length prior respons age
comorbid goal therapi kahl et al blood copiktra
appear much meaning activ ibrutinib btk
inhibitor fl provid potenti materi role copiktra fl believ
effect all-or monotherapi copiktra could answer materi
unmet need patient
exhibit dynamo studi inhl/follicular lymphoma patient
 zinzani et al dynamo phase studi demonstr clinic activ safeti copiktra
patient double-refractori follicular lymphoma eha
copiktra dose twice-daili continu treatment double-
refractori indol nhl patient refractori rituximab
chemotherapi radioimmunotherapi patient patient
dynamo follicular lymphoma fl small lymphocyt lymphoma
sll margin zone lymphoma mzl initi posit complet
data present improv long-term follow-up data
present intern confer malign lymphoma icml
european hematolog associ eha meet primari
endpoint data show orr across patient statist
pre-specifi cutoff respons pr
initi primari analysi fl cohort orr initi determin
irc assess investig exhibit
exhibit initi dynamo studi result inhl/follicular lymphoma
orr
enough fda
encourag
acceler
copiktra result strengthen follicular lymphoma final analysi
final analysi cohort present european
hematolog associ meet analysi addit patient
fl cohort respond rais orr one fl patient achiev
complet respons cr assess investig orr
two exhibit studi met primari endpoint null
hypothesi orr believ respons rate
suffici support acceler approv double-refractori fl patient
current limit treatment option result show rapid
robust activ includ rapid time respons month fl
patient experienc reduct target lymph node month
median durat respons irc fl patient median month
os month patient median time copiktra
month figur use project time therapi fl market model
patient median durat respons mo median
patient studi last anti-canc therapi month
exhibit deepen respons final analysi follicular lymphoma
 zinzani et al dynamo phase studi demonstr clinic activ safeti copiktra
patient double-refractori follicular lymphoma eha
data safeti profil fl need materi attent
affect approv copiktra safeti profil final analysi dynamo
demonstr case grade hematolog event includ neutropenia
anemia thrombocytopenia common grade
event neutropenia diarrhea anemia
investig note limit rate drug discontinu due interest
exhibit right alt unchang addit frequenc
increas lipas occur discontinu due
special interest final analysi seriou opportunist infect occur
less patient princip unchang earli
analysi three death attribut copiktra fl cohort includ
coliti pneumonia occur primari analysi
sepsi syndrom eosinophilia viral infect septic shock led death
primari analysi notabl opportunist infect
materi issu idelalisib occur patient toxic advers
event copiktra need manag quit close
potenti limit factor broader util molecul
howev recent increas focu manag sever due
broader adopt toxic io regimen believ condit
potenti reason well-manag verastem
exhibit copiktra safeti profil double-refractori follicular lymphoma patient final analysi
 zinzani et al dynamo phase studi demonstr clinic activ safeti copiktra patient double-refractori follicular
copiktra opportunity/econom follicular lymphoma fl verastem
acceler approv relapsed/refractori line set
note previous therapeut condit approv condit
though agent receiv full approv estim copiktra price
match cll/sll initi monthli price averag
time drug month given dearth option fl believ
copiktra uptak could materi set wide consid
time treatment double-refractori fl also potenti
consid time earlier line part combin fl account
non-hodgkin lymphoma nhl case new
case year compani estim patient treat
estim util fl patient
relapsed/refractori fl patient treat us peak
similar number eu/row though lower price us peak
util group could exceed million us approach
million rest world effici gain captur via
corpor infrastructur market copiktra overlap
indic fda approv indic lead reason high
probabl approv indic estim fulli tax risk-
weight npv copiktra fl share exhibit
new nhl fl percentag treat fl penetr r/r fl treated- average treatment durat month therapy- price/month launch us revenu
exhibit verastem copiktra follicular lymphoma npv summari
rate
copiktra promis inhibit may directli inhibit
malign t-cell growth shown phase result copiktra
discuss detail mention inhibit either
isoform may also contribut activ modul non-
malign immun cell note commentari blood dr jonathan
brammer state find copiktra activ relapsed/refractori tcl
particular interest field particularli aggress subset
lymphoma
patient
relapsed/refractori treatment avail respons rate
approv therapi low phase result suggest potenti new
therapeut approach patient rare diseas explor
use copiktra monotherapi patient verastem launch
phase studi addit memori sloan ketter cancer center enrol
studi use copiktra romidepsin bortezomib relapsed/refractori
copiktra activ t-cell lymphoma promis phase data publish
blood horowitz et al blood publish promis clinic activ
accept safeti profil relapsed/refractori tcl phase studi
patient peripher tcl cutan tcl ctcl
patient subset broader copiktra phase program patient
receiv copiktra twice daili remain eight
patient copiktra twice daili patient dose
copiktra activ support on-going phase primo studi
cohort orr exhibit left includ pr
respons rate ctcl patient significantli
differ respons observ across subtyp
durat respons month median os cohort
 us royalti royalty- upfront/milestones- total revenu verastem expens cog us royalti royalti cog total net rate tax effect total per valu npv/share
month respect patient median time
drug week rang week addit biomark work
tcl patient day cycl highlight statist signific increas
serum level solubl statist signific
decreas inhibitori subunit could offer earli
sign potenti copiktra respond predict potenti need
confirm addit work
exhibit copiktra activ tcl left includ ptcl right
horowitz et al activ inhibitor copiktra phase trial preclin model t-cell lymphoma blood
copiktra monotherapi safeti tcl patient consist
hematolog malign importantli horowitz et al conclud safeti
profil tcl subset consist overal phase
studi common new grade hematolog decreas
lymphocyt neutrophil sever infect occur
tcl patient pneumonia/lung skin case pjp fungal
infect occur ctcl patient die hsv pneumonia
attribut copiktra seriou occur includ pneumonias/
lung infect coliti pyrexia copiktra discontinu
patient treatment death
due progress overal popul common reason
discontinu alt/ast elev coliti
copiktra combin tcl also explor investigator-initi
effort memori sloan ketter cancer center evalu
potenti copiktra combin tcl group present
initi data show orr ctcl patient treat
copiktra plu romidepsin istodax hdac inhibitor approv
relapsed/refractori ctcl addit copiktra plu bortezomib
velcad proteasom inhibitor approv multipl myeloma mantl
cell lymphoma achiev orr ctcl patient
dose escal limit bortezomib ast/alt elev base
work investigator-initi evalu copiktra/romidepsin
tcl plan though discount rate higher util
copiktra assign modest revenu valuat verastem
exhibit copiktra npv tcl use
copiktra broad activ portend develop option broad-
base activ b-cell growth signal well activ reshap
tumor environ expect copiktra develop multipl addit
way includ combin checkpoint inhibitor immune-
modul standard care addit non-hodgkin
lymphoma subset richter transform mantel cell diffus larg b-
cell lymphoma develop effort could includ combin
car-t therapi upcom novel therapeut modal
addit potenti consider solid tumor arena expect
number approach consid upon initi approv
copiktra us
exhibit approv competit relapsed/refractori cll/sll
note venclexta rituximab approv fda relapsed/refractori cll/sll june
 us royalti royalty- milestones- total revenu verastem- verastem expens cog us royalti royalti cog sg a- total net day rate tax effect total per valu npv/share
zydelig idelalisib gilead zydelig oral twice daili inhibitor
approv fda juli treatment relaps cll
combin rituximab patient would consid rituximab
monotherapi due co-morbid double-refractori fl sll patient
eu zydelig approv treatment relaps cll cll patient
delet mutat treat
therapi double-refractori fl follow seri seriou death
clinic studi line patient combin effort zydelig fda
ema conduct safeti review earli result stop
clinic studi expect materi gilead invest
program recent call gilead announc train
zydelig sale rep promot recently-acquir car-t therapi gilead
report zydelig net sale million million million
respect
zydelig black warn zydelig us label contain black warn
fatal seriou toxic hepat zydelig-tr patient
sever diarrhea coliti pneumon infect
intestin perfor onset sever diarrhea respons
antimotil agent gener occur later treatment pneumon
occur median month begin treatment cheah
exhibit toxic associ idelalisib therapi suggest approach manag base
synthesi consensu panel guidelin us prescrib inform gilead safeti warn
 cheah fowler idelalisib manag lymphoma blood
fda ema issu drug safeti concern regard rate seriou
advers event includ death on-going clinic trial involv zydelig
combin cancer drug connect announc
regard
cmv
occur
halt
includ pjp prophylaxi
gilead confirm fda stop six clinic trial includ phase
studi look expand use earlier line therapi see
combin mortal rate zydelig arm doubl
rate control zydelig death primarili due
increas opportunist infect pneumocysti jirovecii pneumonia pjp
cytomegaloviru cmv importantli death occur patient
receiv pjp prophylaxi cheah fowler blood result
safeti warn addit recommend made better
manag patient zydelig
monitor treatment exhibit believ zydelig ae
learn experi materi reinforc need strictli enforc pjp
prophylaxi regimen util copiktra
earli stage zydelig combin studi stop unexpect safeti despit
larg similar grade safeti profil compar zydelig
rituximab rituximab outsid increas neutropenia vs
addit entospletinib cell receptor modul lenalidomid
immunomodul gener unexpect seriou result closur
sever earli stage trial accord cheah fowler blood zydelig
plu entospletinib limit grade higher pneumon
patient requir ventil support die progress pulmonari
disfunct zydelig lenalidomid rituximab triplet studi
report grade higher dlt transamin lung infect hypotens
rash culture-neg sepsi syndrom patient treat
second studi report grade higher transamin death
due hepat failur respiratori failur base experi
inhibitor combin studi employ
conserv dose-escal scheme fulli character potenti later
zydelig phase relaps cll rituximab stop earli efficaci
evalu zydelig plu rituximab versu rituximab relaps cll patient
inelig cytotox therapi patient must prior
antibody-bas therapi least cytotox regimen oral zydelig
dose twice daili trial stop earli efficaci
analysi given rate zydelig/rituxan vs
placebo/rituxan unadjust cross pre-specified stop criteria
median reach zydelig/rituxan month
control progress occur patient respect treatment
effect gener consist across subgroup delet
month overal surviv rate superior zydelig arm vs hr
orr also significantli favor zydelig vs
respons across studi partial respons lastli zydelig therapi
significantli increas proport patient reduct lymph node
burden vs control vs seriou occur patient
zydelig discontinu treatment due toxic control
seriou discontinu toxic median time zydelig
month vs week patient copiktra duo
exhibit safeti profil idelalisib monotherapi patient
gopal et al inhibit idelalisib patient relaps indol lymphoma nejm
zydelig phase result inhl support double-refractori fl sll
single-arm phase trial evalu twice-daili zydelig
inhl patient refractori rituximab alkyl agent data
publish nejm show orr median os
month respect respons rate similar across subtyp
fl sll mzl lymphoplasmacyt lymphoma
month therapi treatment on-going patient
time analysi patient discontinu treatment owe toxic
studi provid basi acceler approv though without
requir follow addit zydelig studi halt
materi room copiktra refractori fl set
venclexta venetoclax abbvie/roch venclexta venetoclax oral
inhibitor initi fda approv relapsed/refractori cll
delet april recent june approv
broader relapsed/refractori cll/sll popul combin rituximab
though venclexta therapi demonstr solid efficaci challeng
initi regimen drug dose food water glass
water per day lengthi oner titrat regimen cycl
rituximab begin ramp-up period establish due
risk tumor-lysi syndrom tl also requir prophylaxi effort blood
chemistri chang consist tl occur earli hour
first dose dose increas accord label venclexta dose
begin daili escal target mainten dose
tumor lysi syndrom complic titrat may limit venclexta appeal
commun venclexta monotherapi studi current
titrat paradigm tl monitor prophylaxi rate tl
earlier aggress week dose titrat period initi
higher dose rate tl includ death case
acut renal failur product label retrospect analysi real-world
patient conduct mato et al titrat period
patient achiev fda recommend dose daili nearli patient
receiv tl prophylaxi receiv rasburicas
patient least plan hospit stay monitor
exhibit venclexta/rituximab os relapsed/refractori cll/sll investig assess
seymour et al venetoclax-rituximab relaps refractori chronic lymphocyt leukemia nejm
phase murano studi rituximab relapsed/refractori cll/sll
rituximab dose day cycl begin venclexta titrat
vs bendamustine/rituximab relapsed/refractori cll/sll protocol
allow crossov venclexta/rituximab treatment arm primari
endpoint result publish seymour et al nejm
month follow-up median investigator-assess
reach venclexta arm vs month bendamustin
respect rate investig assess
independ review
reach venclexta month bendamustin
rate cr cr incomplet hematolog recoveri similar
venclexta bendamustin vs first secondari
endpoint test hierarch analysi orr venclexta vs
bendamustin regard os rate surviv
venclexta vs bendamustin
venclexta/rituximab safeti venclexta/rituximab combin
describ prohibit toxic seymour et al nejm
phase murano studi grade occur patient
venclexta vs bendamustin neutropenia common
grade event grade tumor lysi syndrom occur
venclexta patient vs bendamustin rate grade
infect infest respect exhibit
seymour et al venetoclax-rituximab relaps refractori chronic lymphocyt leukemia nejm
venclexta monotherapi line cll delet single-arm phase
trial publish lancet oncol assess venclexta monotherapi cll
patient relapsed/refractori diseas delet primari
endpoint orr median follow-up month orr
independ central review among patient enrol support
acceler approv molecul grade includ neutropenia
infect anemia thrombocytopenia
half patient seriou advers event common
pyrexia autoimmun hemolyt anemia pneumonia febril
neutropenia within day last venclexta dose
diseas progress owe non-treatment-rel
aliqopa bayer aliqopa copanlisib bayer
rate highli select iv-onli pan-class inhibitor
predominantli select isoform aliqopa valu
nm /// isoform respect aliqopa receiv
fda acceler approv patient relaps fl receiv
least prior system therapi septemb base primarili
orr achiev relaps fl patient open-label single-arm phase
studi weekli iv therapi includ black warn
label due lower immune-medi advers event although
materi grade rate
hyperglycemia hypertens
phase orr support acceler approv fl open-label
single-arm studi enrol patient doubl relapsed/
refractori inhl weekli iv aliqopa week cycl
primari analysi report dreylin et al median durat treatment
week remain drug orr includ cr
patient stabl diseas diseas subset orr
cr fl patient cr mzl patient overal
estim median durat respons day estim median
day updat analysi eight month later patient
remain therapi median treatment durat week orr
declin one patient three addit patient achiev cr
includ new fl median durat respons
month median month median os reach
exhibit aliqopa materi anti-tumor efficaci indol nhl
dreyl copanlisib patient relaps refractori indol b-cell lymphoma
aliqopa differenti safeti profil primari analysi
median safeti follow-up week aliqopa demonstr low rate
compar inhibitor common treatment-rel
includ transient hyperglycemia hypertens grade
higher rate respect class event includ
pneumon coliti prophylaxi opportunist
infect mandat non-fat opportunist infect occur
elev alt ast occur patient princip
grade respect patient die includ drug-rel
lung infect respiratori failur thrombot event extend
follow median week safeti addit patient discontinu
therapi total worst-grad seriou larg
unchang longer follow new treatment-emerg death
dreyl et al updat safeti efficaci copanlisib trial patient
relaps refractori indol b-cell lymphoma incid late-onset sever toxic abstract
phase label expans effort on-going bayer continu develop aliqopa
b-cell malign on-going phase trial support full
approv double-refractori inhl complet around yearend
phase studi evalu combin rituximab
standard chemoimmunotherapi inhl
patient relaps least rituximab contain regimen
studi read respect primari
endpoint
defactinib fak inhibitor io applic
clinicaltri gov access btig research
fak inhibitor defactinib progress clinic io
verastem multipl studi on-going evalu defactinib focal adhes
kinas fak inhibitor combin approv io therapeut bavencio
avelumab keytruda pembrolizumab fak activ variou tumor
shown drive exhaust cell recruit treg
tumor microenviron among effect permit enhanc
growth fak-express tumor fak inhibit therefor potenti
creat favor tumor microenviron cell focus anti-canc
therapi checkpoint inhibitor exhibit verastem conduct
phase trial antibodi bavencio ovarian cancer
washington univers school medicin cancer research uk
conduct earli phase trial antibodi keytruda advanc
nsclc pancreat cancer mesothelioma though rel earli
studystatuscombinationtumorsest gemcitabineiniti data mesothelioma tumor pancreaticcarboplatin-resist ovarian
clinic defactinib demonstr meaning proof-of-concept
set program could establish materi potenti defactinib
offer materi upsid vstm share
exhibit fak inhibit reprogram tumor microenviron
symeonid et al fak-inhibit open checkpoint immunotherapi pancreat cancer immunoth cancer
defactinib io/chemo combo data pancreat cancer intrigu
present encourag phase data investigator-initi trial
defactinib keytruda gemcitabin advanc cancer patient wang-
gillam et al patient enrol dose-escal includ
pancreat ductal adenocarcinoma pdac three biliari tract five
cancer eight pdac patient evalu respons one achiev
pr three achiev stabl diseas diseas control rate
median time therapi day evalu patient
day pdac patient mechanist pair pdac biopsi data show
tripl therapi increas prolifer t-cell decreas treg
tumor associ macrophag consist less suppress tumor
microenviron intrigu earli data program
enrol expans phase patient advanc pdac mayo
 receiv recommend phase dosedefactinib
twice daili keytruda day day cycl gemcitabin
day cycl
xu et al cancer stem cell inhibitor defactinib exhibit synergist
anti-cancer activ preclin model mesothelioma abstract eortc
regulatori fda health agenc oversight compani whose
main busi drug develop verastem subject rigor
strenuou regulatori requir us food drug administr
fda intern medicin develop regulatori agenc
new drug approv market promot approv drug
product also regul fda relat agenc throughout globe
though compani specif focu ethic prescript pharmaceut
place signific risk oper believ risk time
greater less research-bas drug develop
compani biotechnology/biopharmaceut industri
materi depend upon copiktra success materi portion
verastem estim revenu cash profit estim come
develop copiktra late stage oncolog asset fda regulatori
review monotherapi treatment relapsed/refractori cll/sll fl
report copiktra clinic benefit efficaci safeti suffici satisfi
regulatori author fda ema larg anticip potenti
revenu cash profit expect result approv risk
could materi restrict compani sever way like materi
neg affect vstm share note valuat comment
copiktra develop program materi investor interest believ
repres materi portion verastem valuat therefor copiktra
approv progress effici label expans effort
materi risk vstm share could trade neg result capit
loss vstm sharehold
manufactur fda oversight fda quit vigil inspect
drug biolog manufactur plant us global
verastem and/or contract manufactur could therefor subject risk
fda manufactur meaning problem
verastem manufactur oper could materi potenti
product consequ could materi neg affect verastem
oper vstm share
reimburs risk patient physician insur may ascertain
benefit valu verastem brand therapeut benefici light
particular insur could requir rigor requir prior author
payment prescript approv manag care
significantli accept verastem product price arrang compani
revenu could insuffici obtain profit vstm sharehold
could experi neg return result
commerci risk copiktra particip highli competit market
exist develop stage therapeut verastem experi
market drug product current establish market capabl
compani unabl achiev signific product sale necessari
profit vstm share could materi harm also verastem
fail obtain intern commerci partner product vstm
share could also significantli harm
financ risk vstm share may subject financ risk compani
may need rais addit capit support commerci launch
copiktra cll/sll fl may need rais addit fund complet
studi indic copiktra and/or opportun
pipelin verastem unabl obtain licensur us addit
intern market product unabl suffici differenti
compar gener brand option indic
pursu materi addit dilut exist sharehold possibl
investor percept vstm share could substanti harm
addit risk verastem incur expect incur signific cost
result law regul relat corpor govern
matter verastem subject feder state foreign healthcar law
regul implement chang healthcar law
regul could advers affect busi result oper
verastem statement except per share amt product revenu duvelisib total us duvelisib cll/sll us duvelisib fl us duvelisib lymphoma us defactinib total us other/collab proprietari drug revenu verastem us mileston royalti revenu royalti partners- up-front mileston partners- total roylti upfnt milestn payments- revenue- total verastem revenue- expens oper interest interest incom financ incom incom pre-tax tax tax tax convert prefer secur transact net incom loss effect fulli comprehens incom comprehens incom ex-charg eff ex-charg comprehens incom eff o/ o/ expens sale -- sale product year year growth -- ex-charg verastem inc sec document btig estim contact inform robert bert hazlett manag director btig research
verastem balanc sheet statement flow except per share amount
sheetasset investments/mktb account prepaid current current defer financ properti equip restrict total account accru current current long-term equiti common addit paid accumul comprehens accumul equiti sharehold total liabil sharehold statement oper activ net incom depreci non-cash compens amort avail sale account prepaid expens current account accru expens oper oper invest activ capit expenditur purchas matur invest financ activ defer financ proce iss common stock proceeds/retir use settl restrict stock financ cash increas decreas cash verastem inc sec document btig estim contact inform robert bert hazlett manag director btig research
btig cover compani mention report
appendix analyst certif import disclosur
